Clinical trial

A Randomized Placebo Controlled Study to Show That Rasagiline May Slow Disease Progression for Parkinson's Disease

NCT00256204

Study summary

ClinicalTrials.gov

A Randomized Placebo Controlled Study to Show That Rasagiline May Slow Disease Progression for Parkinson's Disease

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record Rasagiline Mesylate Normalized identity: rasagiline mesylate View linked drug · Find medicine records · Find other trials using this name

OTHER · Unmapped registry intervention Placebo Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2005-11-01

PhasePHASE3

Conditions

Parkinson's Diseaseverified · MONDO: Parkinson disease

Interventions

Rasagiline MesylateDRUG · verified · RxNorm: rasagiline mesylate

PlaceboOTHER

Sponsors & collaborators

Teva Branded Pharmaceutical Products R&D, Inc.lead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00256204 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.